Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Firm Agrees to Refund to Settle Suit Over Weight-Loss Pills

By Drug Discovery Trends Editor | March 2, 2015

Salt Lake City-based company has agreed to pay refunds to consumers who purchased its weight-loss tablets to settle a class-action lawsuit that claimed its advertising slogan, “Eat All You Want & Still Lose Weight,” was deceptive.

Under the proposed settlement, Basic Research will pay a refund of $25 per box after being sued by law firms on behalf of consumers who purchased the product called Akavar beginning in 2007.

A Basic Research representative didn’t respond to requests for comment. But the company has denied any wrongdoing and would still be able to use the slogan under the proposed agreement.

Salt Lake City attorney Jon Harper, who represents consumers, told The Salt Lake Tribune that he couldn’t comment other than to say the litigation was resolved “on terms satisfactory to the parties.”

In 2007, a proposed class-action lawsuit was filed in U.S. District Court in Utah against Basic Research on behalf of consumers who bought Akavar based on the company’s advertising. A second similar complaint was filed in state court in California in 2008.

The two lawsuits, which were eventually consolidated into one action in federal court in Utah, said the company lacked a scientific basis for the weight-loss claims and was deceiving consumers.

Akavar was sold by major retailers and marketed as a wonder pill in which consumers could “Eat All You Want & Still Lose Weight … (And we couldn’t say it in print if it wasn’t true!)”

The company sold 60 capsules for $39.99 and two bottles for $79.98 with a third one for free, and sales brought in millions of dollars, according to court documents.

In 2006, the Federal Trade Commission fined Basic Research $3 million and reached a settlement requiring the company to have a scientific basis for the claims of its products.

The FTC and Basic Research sued each other in 2009 in federal court in Utah over whether the company was violating the 2006 deal.

But last year, U.S. District Judge Clark Waddoups sided with Basic Research, noting two of four case studies done in 2001 suggested the herbal compounds in Akavar helped users to lose weight. His decision is cited in the proposed settlement of the class-action lawsuit, The Tribune reported.

Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50